Immunisation of Chickens With H9N2 Avian Influenza Virus Leads to Differential B-Cell Repertoire Development

H9N2 avian influenza does much of its damage without the spectacle associated with the deadliest bird-flu outbreaks. In chickens it often causes relatively mild disease, yet infected flocks can grow poorly and produce fewer eggs. Other infections may become harder to withstand. The virus circulates widely, which gives it repeated opportunities to change as it passes from bird to bird. It can occasionally infect people and has contributed genetic material to other influenza viruses. A quiet presence in poultry can therefore matter well beyond one apparently healthy flock.

Vaccination is one of the main ways farmers and animal-health authorities reduce that circulation. Many programmes use an inactivated vaccine, made from virus treated so that it can no longer reproduce. Immune cells still encounter its recognisable structures and prepare for a future infection. A live virus enters through respiratory tissue and multiplies inside cells, creating a different encounter. Both experiences can produce antibodies. My co-authors and I wanted to know whether the immune systems arriving at that result had taken the same route.

I led the experimental study as first author. Groups of chickens received different histories of H9N2 exposure, including vaccination, infectious challenge and repeated combinations. This controlled design allowed us to look beneath a familiar laboratory measurement. The amount of virus-binding antibody in blood tells us whether a response occurred. It says far less about the families of immune cells producing that antibody or whether two birds with similar totals reached them through the same biological process.

Those families begin with B cells. Each B cell carries a receptor shaped to recognise a particular molecular feature. When the receptor binds its target and the surrounding immune signals support a response, that cell can multiply into a clone of related descendants. Some release antibodies, soluble versions of the receptor that travel through blood and tissue. Others become memory cells that remain after the immediate threat has passed. The complete collection of these recognitions forms the B-cell repertoire.

Diversity emerges because developing B cells assemble their antibody genes from separate inherited segments. The combinatorial process creates many possible receptors from a smaller genetic toolkit. Infection then gives certain cells a reason to expand. A repertoire therefore contains two histories at once: the possibilities generated during development and the particular clones selected by experience. Sequencing the genetic instructions for antibodies allows researchers to read part of that history.

We focused on IgM and IgY. IgM often appears early in a response. IgY performs several functions similar to mammalian IgG and can contribute to longer-lasting protection. Samples came from several tissues because immunity is organised across the body rather than contained in one tube of blood. The spleen helps coordinate responses carried through the circulation. The bursa of Fabricius, an organ unique to birds, is central to B-cell development. Respiratory tissue records an encounter closer to the virus's route of entry.

High-throughput sequencing produced large numbers of antibody-gene reads from these sites. Computational analysis grouped related sequences into clones and compared their abundance across birds. A clone present in several individuals is described as public, while one detected in a single bird is private. Public does not mean universal or automatically useful. It means separate immune systems have generated closely similar answers, a convergence that can point researchers toward recurring biology.

The study found that public IgM and IgY clones made up a substantial part of the observed response. Their pattern depended on both the birds' immunisation history and the tissue examined. Certain expansions appeared in vaccinated groups, while others were associated with infection. A second vaccination did not simply produce a larger version of the first repertoire. Vaccination followed by infection created its own arrangement of prominent clones. The order and setting of exposure shaped which cellular families came forward.

Expansion is only one part of the response. After activation, some B-cell descendants acquire small changes in their antibody genes. Cells whose receptors bind more effectively can receive stronger signals to survive and multiply, a process that gradually refines recognition. Related sequences in the repertoire preserve traces of this maturation. The amount and pattern of change may help explain why repeated exposure strengthens some responses while narrowing others around a smaller set of targets.

That difference makes biological sense. An injection deposits antigen in tissue where local immune cells collect it and carry information into nearby immune structures. Influenza infection begins mainly along the respiratory tract, accompanied by viral replication and signals from damaged cells. The immune system sees a related target inside a different alarm. Location and inflammation influence which B cells receive help, where they expand and whether their descendants enter memory. The final antibody level can flatten those distinct experiences into one number.

Tissue differences added another warning about simple interpretation. A clone abundant in the spleen might remain scarce in the trachea or bursa. An absent sequence may exist below the detection threshold or in a site that was never sampled. Sequencing gives a detailed view of the material collected, rather than an inventory of every B cell in the bird. Comparing groups therefore depends on consistent sampling and enough individuals to separate a treatment pattern from ordinary biological variation.

The experimental groups were necessarily limited in size, which makes the repeated patterns across birds informative while leaving rare responses harder to characterise. Sequence-processing choices also affect where one clone is separated from a close relative. Thresholds help distinguish genuine expansion from background reads, yet no threshold is biologically perfect. Reproducible analysis and access to the underlying data allow other researchers to test whether a result survives a different reasonable choice.

Function remains the crucial next question. A shared clone may bind H9N2 without blocking infection. Researchers need to isolate or recreate the corresponding antibody and test whether it prevents the virus entering cells, recognises several H9N2 variants or recruits other immune mechanisms. Repertoire sequencing identifies candidates and relationships. It cannot turn a sequence alone into proof of protection. That boundary matters whenever a visually striking expansion appears in the data.

Farm conditions widen the boundary further. Chickens vary in genetics and age. Maternal antibodies passed from a hen can interfere with early vaccination, while stress or another infection changes the immune response. A schedule that creates an interesting repertoire in controlled birds still has to reduce illness and viral shedding in ordinary flocks. Shedding, the release of virus from an infected bird, determines whether apparent individual protection also slows transmission.

This is where the work connects with One Health, the recognition that human and animal health are linked through shared environments and pathogens. Controlling H9N2 improves poultry welfare and protects livelihoods. Fewer infections also mean fewer opportunities for influenza viruses to reassort, a process in which strains infecting the same cell exchange genome segments. Most combinations will fail. The continuing circulation of H9N2 keeps creating chances for one that does not.

Future studies can follow important clones for longer and connect them with memory, neutralisation and reduced shedding. They can compare vaccine formulations that stimulate immunity closer to the respiratory tract or test whether a public response appears across chicken breeds. Repertoire data may eventually help researchers choose promising schedules before a full challenge study, although direct evidence of health and transmission will remain indispensable.

Memory deserves special attention because it may remain quiet between exposures. A bird can carry memory B cells while the amount of circulating antibody declines. When the virus returns, those cells may expand quickly and produce refined antibodies. Measuring blood alone could underestimate that reserve. Following repertoire sequences into a later challenge would reveal which clones persisted and whether their return coincided with faster control of the infection.

Vaccination and infection both leave evidence in the blood, yet the immune response is more than the concentration of antibody at one moment. It is a population of cells shaped by where the encounter occurred and what came before it. Our study showed that those histories remain visible in the repertoire. Reading them gives vaccine science a deeper question than how much antibody was made: which biological memories are being built, and what will they allow the bird to do when influenza returns?